Key Takeaways
- 37% revenue growth, capacity still the bottleneck: Q1 revenue of ₹449 crore grew 37% YoY, driven by semaglutide commercialization and new customer wins, while the company remains capacity-constrained with more demand than it can serve.
- FY28 guidance reiterated with conviction: Management reaffirmed the $400 million organic revenue and 40% EBITDA margin target, now underpinned by visible capacity coming online and a broadening customer base across all four business lines.
- The semaglutide opportunity is scaling fast: India generic pen volumes grew from under 2,000 to 150,000–160,000 per month within a year, and OneSource already holds over 40% market share of pens sold in India.
- Margins are on an upward ramp, not yet at steady state: EBITDA of ₹123.3 crore (up 39% YoY) benefited from a favorable mix shift toward drug device combination, but new-line opex has been upfronted, so operating leverage will build as revenue fills the new capacity.
- What to watch next quarter: The second cartridge line commercializing this quarter, the pace of new customer onboarding onto that line, and any update on the soft gelatin greenfield.
Capacity Expansion: The Core Growth Unlock
- From one line to three: The existing sterile line has been heavily overbooked; a second cartridge line commercializes this quarter (Q2 FY27), doubling sterile production days, and a third line will be installed within FY27, making OneSource one of very few global CDMOs offering this scale with end-to-end drug device combination capability.
- A fourth line already planned: A fourth sterile line will be available later in FY28 to cover demand from new markets opening from FY28–29 onward, signaling management's confidence that the demand pipeline extends well beyond current capacity.
- Batch sizes doubling: The company is working with customers to increase batch sizes from mostly 200 liters to 500 liters, which would significantly increase output from the same sterile days and should be achievable for most geographies quickly.
- Lines are fungible: Existing customers will be moved to the new line as well, and customers will be serviced from both lines; management states there are sufficient customers and demand on both lines for this year.
- Capacity-first CDMO model: Management emphasized that as a CDMO, it must build capacity and capability first, then add customers, because it cannot start building only when customers arrive. The new lines are now enabling onboarding of customers that were previously turned away.
Neeraj Sharma: "Till now we have been really struggling to meet the demand because of one line was heavily overbooked. And the reason for us to add new line, not new line, but new lines is because, we have a very clear visibility on the demand."
Semaglutide & GLP-1: The Demand Engine
- Canada launch is the anchor: The semaglutide commercial launch in Canada, the largest off-patent market available today, represents a meaningful step up; all three approvals in that market are with OneSource, and two partners have already launched.
- India market share leadership: Many customers launched on day one in India, and as of June 26, more than 40% of generic pens sold in India are manufactured at OneSource's site.
- Supply, not demand, has been the constraint: India pen volumes grew from under 2,000 to 150,000–160,000 per month within a year, still with significant supply constraints; generics are providing access to latent demand that branded pricing had left unserved.
- DRL disruption absorbed: Despite the temporary supply disruption announced by Dr. Reddy's, OneSource's available capacities remain full because its customer base spans markets and companies, pulling demand while DRL supplies resume.
- Customer base expanding: The first new GLP customer came on board last quarter, something previously impossible due to the supply gap; new capacity will support supplies to DRL when they resume and to multiple countries opening in the remainder of the year.
- Tirzepatide first-to-file: Two customers successfully obtained first-to-file status in the US with tirzepatide, positioning OneSource for the next wave of GLP-1 patent expiries.
Neeraj Sharma: "Despite the temporary disruption in supplies which has been announced by Dr. Reddy's, our available capacities are full, thanks to really our customer base which spans across markets and across companies. And this has really helped us pull the demand while the DRL supplies resume."
Business Lines: Diversification Beyond GLP-1
| Business Line | Status | Growth Drivers |
|---|---|---|
| Drug Device Combination | ▲ Scaling | Semaglutide commercialization in Canada and India; Europe opens FY29–30, then US with FTF customers; order book described as "very clear." |
| Biologics | ▲ Pipeline building | Formycon partnership added; RFP funnel 4x what it was a year ago, spanning innovators, biosimilars and animal health; commercial revenues from current customers start FY29 onwards; near-term revenues are development MSAs. |
| Soft Gelatin | ▲ CDMO pivot | Previously captive to Strides' IP-led products; now offering CDMO services with significant interest after European players faced challenges; new capacity expected fully taken over 12–15 months; greenfield initiated. |
| Injectables | ▬ Steady scarcity play | Focused on products requiring dedicated manufacturing (penicillin, one of few FDA-approved plants globally) and products perpetually on FDA shortage list; customers value sustained supply over low prices; new pre-filled syringe and lyophilization capacity being added. |
- Biologics end-to-end proposition: OneSource can take a product from gene to the final patient-ready pack, including drug substance scale-up, fill-finish on the same site, and assembly in an autoinjector or pen injector, a rare integrated offering.
- Soft gelatin greenfield underway: The process of starting a greenfield has been initiated, with an update expected over the next quarter or so; current site capacity utilization expected to be completed over the next two years.
- Injectable plant shutdown: A shutdown on one sterile injectable site starts Q2 and lasts between Q2 and Q3 to add pre-filled syringe and lyophilization capacity; new capability will be available for full year FY28.
- Oncology soft gel NDA: Secured with a top 10 US generic player for a brand product (not ANDA); customer expected to launch in the current quarter, though the market is small and not expected to contribute significantly to near-term revenue.
Margins: Upfronted Costs, Back-Ended Leverage
- Sequential improvement driven by mix: Q1 EBITDA margin improvement came from a higher contribution of the drug device combination business; the base business (soft gelatins, injectables) is H2-heavy, with soft gel contribution picking up when flu seasons begin.
- New-line opex is front-loaded: Profitability on line one is not yet optimal because opex for new lines has been upfronted; operating leverage will improve as new lines come online and revenue ramps with limited incremental opex.
- Revenue ramp in H2: Management expects sequential quarter-on-quarter improvement in both revenue and EBITDA, with the new line's revenue contribution ramping in the second half of FY27.
- Customer mix shifting to commercial sales: The mix will be significantly more commercial sales (CSA) than MSAs going forward, driven by new capacity coming online and customers moving from development to commercial supply.
- Geopolitical freight impact muted: Middle East disruptions have increased shipment times and container shortages, but all contracts are ex-works, so additional time and cost are picked up by customers.
Biologics: The FY29 and Beyond Story
- Pipeline build in progress: The RFP funnel has grown 4x over the last 12–15 months, spanning innovators, biosimilars and animal health companies; the Formycon partnership adds a marquee global biosimilars player.
- Revenue trajectory: The next two years will be mostly development MSA revenues; commercial revenues from current biologics customers will start coming in FY29 onwards, making biologics a significant contributor to growth beyond FY28.
- Capacity expansion on the horizon: Current biologics capacity will require expansion across both mammalian and microbial platforms; capex will be significantly lower than what was invested in drug device combination, and timing will be "as and when" required based on pipeline visibility.
- Animal health adds a third leg: An additional animal health contract was won last quarter, complementing the innovator and biosimilar customer segments.
Neeraj Sharma: "Our pipeline, I think this is what, it's important for us to say, that the pipeline continues to be built with our RFP funnel today is almost 4x of what it was just over a year ago. And this spans across innovators, biosimilars, as well as animal health companies."
Regulatory & Operational Resilience
- Exemplary compliance track record: 12 successful inspections this quarter across regulatory inspections and customer audits, including two surprise FDA audits across two sites, reinforcing the company's ability to operate in scarcity markets where compliance failures by competitors create supply gaps.
- Nine new launches and six new logos: Added during the quarter, reflecting the broadening customer base as capacity visibility improves.
- US tariff stance: Management sees the tariff announcement as too early to assess but does not believe it will cause any long-term harm to the company or its customers, expecting the pattern of changes and backdowns to continue.
Neeraj Sharma: "Our injectable business is very, very focused on scarcity play... we either go for products which are very, which require dedicated manufacturing like penicillin. We have one of the few FDA-approved penicillin plants anywhere in the world with an absolutely excellent compliance track record. Thanks to which, we have a significant share of penicillin in the US and the products which are perpetually in FDA shortage list."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Organic revenue target | $400 million | FY28 |
| EBITDA margin target | 40% | FY28 |
| Second cartridge line commercialization | Doubles sterile production days | Q1 FY27 |
| Third sterile line installation | Makes OneSource one of very few global CDMOs at this scale with end-to-end capability | Within FY27 |
| Fourth sterile line availability | Covers demand from new markets opening FY28–29 | FY28 |
| Soft gelatin capacity fill | New CDMO capacity completely taken | Next 12–15 months |
| Injectable new capability (PFS, lyo) | Available for full year | FY28 |
| Biologics commercial revenues | From current customers | FY29 onwards |
| Sequential revenue and EBITDA improvement | Quarter-on-quarter | Through FY27 |
Key Metrics
| Metric | Q1 FY27 |
|---|---|
| Revenue | ₹449 crore, +37% YoY |
| EBITDA | ₹123.3 crore, +39% YoY and +34% QoQ |
| EBITDA margin | 27.5% (per an analyst's math) |
| FY28 organic revenue guidance | $400 million, reiterated |
| FY28 EBITDA margin guidance | 40%, reiterated |
| Generic pen market share (India) | >40% of generic pens sold, as of June 26 |
| New product launches | 9 during the quarter |
| New customer logos added | 6 during the quarter |
| Regulatory inspections passed | 12, including 2 surprise FDA audits across 2 sites |
| RFP funnel growth | ~4x versus just over a year ago |
| Capex program committed | ~80% of US$100 million capex committed |
| Sterile days per line per year | ~225 days per line; FY28 expected 675 days across 3 lines |
| Canada semaglutide approvals held | 3 out of 3 approvals in market with OneSource |
| India weight-loss pen market volume | 150,000–160,000 pens/month, up from <2,000 pens/month a year ago |